NICE has recommended natalizumab for adults with highly active RRMS, citing pregnancy suitability, biosimilar value and NHS ...

NICE has recommended Tysabri and biosimilar Tyruko as an option for patients with highly active relapsing-remitting multiple ...

NICE has backed NHS use of natalizumab, a key treatment option that is safe for use in pregnancy, for more patients with ...

NICE has recommended the drug, natalizumab, as an option for adults with relapsing-remitting MS (RRMS) that remains highly active after a full course of at least one disease-modifying therapy, and for ...

Good physical performance is associated with better cognition in people with relapsing-remitting MS, according to a recent study by the University of Eastern Finland. Good functional capacity was also ...

Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and ...

Two new sub-types of multiple sclerosis (MS) were discovered by researchers from Queen Square Analytics and University ...

—To some extent, yes, say the results of a recent systematic review and meta-analysis. But were escalation therapies any more effective than platform therapies in boosting cognition? Share on Facebook ...

This study demonstrated progressive CP enlargement over time in individuals with RRMS, averaging 1.4% a year with significant variation per participant. CP enlargement correlated with the expansion of ...

A stem cell treatment commonly used for blood cancer appears effective in treating one form of MS The treatment has been available since the 1990s but questions about safety and difficulty have ...